"I may have just missed it but I couldn't find any mention of how often patients in the mCRC trial would be dosed, just that they would test the response to two different dosages, 350 mg and 700 mg. Can anyone inform me as to frequency? Ganesha"


This is the only info I can find...

"The phase 2, open-label, multicenter study will randomly assign approximately 60 patients with CCR5-positive MSS mCRC to receive either 350 mg or 700 mg of leronlimab. Patients will be divided into 2 cohorts, with an initial safety lead-in group receiving the 350 mg dose before advancing to the higher dose group. Leronlimab will be administered weekly, while TAS-102 and bevacizumab will be given on a 3- or 4-week schedule within a 4-week cycle.

https://www.targetedonc.com/view/fda-clears-p...stable-crc